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anandamide (6  !  10 –5  M ) on salivary secretion. Lipopolysac-
charide (5 mg/kg/3 h) injected intraperitoneally and ethanol 
(3 g/kg/1 h) injected intragastrically inhibited the salivary se-
cretion induced by the sialogogue metacholine; this inhibi-
tory effect was blocked by CB1 and/or CB2 receptor antago-
nists. Similar to the hypothalamus, these effects seem to be 
mediated by increased anandamide. In summary, similar 
mechanisms mediate the inhibitory actions of endocanna-
binoids and cannabinoids in both hypothalamus and sub-
mandibular gland during drug consumption and inflam-
mation. 
 
Copyright © 2007 S. Karger AG, Basel 
 Role of the Endocannabinoid System in the 
Hypothalamic-Pituitary Reproductive Axis and 
Salivary Secretion 
 It is well established that the major active ingredient of 
marijuana,   9 -tetrahydrocannabinol (THC), is capable 
of suppressing the reproductive function  [1] . Previous 
studies indicate that the inhibitory effect of THC on the 
reproductive axis is exerted mainly at hypothalamic lev-
el by inhibiting luteinizing hormone-releasing hormone 
(LHRH) release with the consequent decrease in lutein-
izing hormone secretion by the pituitary, thereby inhibit-
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 Abstract 
 During marijuana and alcohol consumption as well as during 
inflammation the reproductive axis is inhibited, mainly 
through the inhibition of luteinizing hormone-releasing 
hormone release. In male rats, this inhibitory effect is medi-
ated, at least in part, by the activation of hypothalamic can-
nabinoid type 1 receptors (CB1). During inflammation, this 
activation of the endocannabinoid system seems to be 
 mediated by an increase in TNF-  production followed by 
anandamide augmentations, similarly the effect of intragas-
tric administration of ethanol (3 g/kg) seems to be due to an 
increase in anandamide. On the other hand, a number of dif-
ferent actions mediated by the endocan nabinoid system in 
various organs and tissues have been described. Both can-
nabinoid receptors, CB1 and CB2, are localized in the sub-
mandibular gland where they mediate the inhibitory effect 
of intrasubmandibular injections of the endocannabinoid 
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ing gonadal function  [2] . In vitro studies performed by 
our group in 1990 showed that THC (10 –8  M ) inhibited 
the norepinephrine-stimulated (NE; 5  !  10 –5  M ) as well 
as the dopamine-stimulated (5 !  10 –5  M ) LHRH release 
in medial basal hypothalamic explants (MBH)  [3] . 
Around that time, 2 subtypes of G protein-coupled can-
nabinoid (CB) receptors were identified: the CB1 central 
receptor subtype, which is mainly expressed in the brain 
 [4] , and the CB2 peripheral receptor subtype, which ap-
pears to be particularly abundant in the immune system 
 [5] . Both CB1 and CB2 receptors are coupled to G i/o pro-
teins and respond to their ligands by inhibiting adenylyl 
cyclase (AC) activity  [6] . A few years later, 2 endogenous 
cannabinoids were discovered and purified, arachidonyl-
ethanolamide (anandamide, AEA) and arachidonoyl 
glycerol (2-AG). Both endocannabinoids derive from ara-
chidonic acid and bind with high affinity to CB receptors 
 [7] . Additionally, selective antagonists have been devel-
oped for CB receptors, such as AM251 and SR141716A for 
CB1, and AM630 and SR144528 for CB2.
 The CB1 receptors are localized in different areas of 
the rat brain  [8] . In particular, we showed the presence of 
CB1 receptors in the preoptic hypothalamic area and in 
the periventricular MBH of male rats, regions that con-
tain the neuronal somas and terminals involved in the 
synthesis and release of LHRH, respectively  [9] . Using 
double immunohistochemistry techniques, no colocal-
ization of CB1 receptors with LHRH-immunoreactive 
neurons was observed. However, CB1 receptor-immuno-
reactive neurons were shown adjacent to the third ven-
tricle, an area that contains axons from LHRH neurons. 
Having demonstrated the presence of CB1 receptors in 
the MBH, we studied the effect of AEA on LHRH release. 
Firstly, we showed that AEA (10 –9  M ) decreased by 70% 
the N-methyl  D -aspartic acid (NMDA)-stimulated LHRH 
release from MBH incubated in vitro  [10] . Secondly, we 
demonstrated that the same concentration of AEA sig-
nificantly decreased the forskolin (FRSK)-induced cyclic 
AMP (cAMP) content and LHRH release. These inhibi-
tory effects of AEA were prevented by the selective CB1 
receptor antagonist, AM251 (10 –5  M ), confirming the 
participation of the endocannabinoid system as a modu-
lator of LHRH release in male rats. AEA (10 –9  M ) also 
significantly increased the release of   -aminobutyric 
acid (GABA) from the MBH, but had no effect on   -
endorphin release. Moreover, bicuculline (10 –4  M ), a
GABAergic antagonist, was capable of totally blocking 
the inhibitory effect of AEA on NMDA-stimulated LHRH 
release. However, naltrexone (10 –6  M ), an opioid receptor 
antagonist, did not modify the inhibitory effect of AEA. 
These data confirmed the GABA-mediated inhibition of 
LHRH release induced by endocannabinoids. Moreover, 
CB1 receptors were observed on hypothalamic GABAer-
gic neurons [M. Herkenham, pers. commun.]. An in-
volvement of the opioid system could not be shown.
 The submandibular gland (SMG) is one of the major 
salivary glands, together with the sublingual and parotid 
glands. In vitro studies on rat SMG slices showed that  3 H-
THC was transported into and accumulated by salivary 
tissue  [11] . Also, it has been demonstrated that THC de-
creased electrically stimulated salivary flow in dogs by a 
mechanism involving a decrease in acetylcholine release, 
which results in reduction of blood flow to the SMG  [12] . 
 We have shown immunohistochemically that both 
CB1 and CB2 receptors are present in acinar and ductal 
components of the SMG, and evidence of their role in di-
minishing saliva secretion was obtained  [13] . Thus, can-
nabinoid receptors could be associated with the 2 funda-
mental mechanisms of salivary secretion: acinar release 
of protein and fluid, and ductal modification of the pri-
mary secretion. 
 Two major signal transduction pathways are implicated 
in salivary gland cells. One involves the generation of 
cAMP and the other involves the breakdown of plasma 
membrane polyphosphoinositides  [14] . cAMP induction 
stimulates some salivary functions, such as salivary flow 
rate and secretion of proteins. CB receptors activation in-
hibits AC activity with a consequent decrease in cAMP 
upon binding of cannabinoids  [6] . We demonstrated that 
AEA markedly reduced FRSK-increased cAMP levels in 
SMG of male rats incubated in vitro, and this effect was 
blocked partially by either CB1 or CB2 receptor antago-
nists, and completely when both antagonists were used to-
gether, indicating the involvement of both receptors in 
SMG physiology.
 Salivation is controlled by the autonomic nervous sys-
tem not only by direct activation of salivary gland recep-
tors, but also by activation of central mechanisms. In fact, 
it has been reported that atropine, a muscarinic antag-
onist, injected intracerebroventricularly, reduced the 
 salivation induced by pilocarpine, a muscarinic agonist, 
injected intraperitoneally, suggesting that pilocarpine 
passes the blood-brain barrier and acts on central mus-
carinic receptors, activating autonomic efferents to in-
duce salivation  [15] . We have recently demonstrated that 
the sialogogue metacholine (MC) injected through the 
femoral vein not only acted on its receptors in the SMG, 
but also on its receptors in the brain, stimulating efferent 
responses to the periphery that are modulated by the hy-
pothalamic endocannabinoid system. 
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 We also demonstrated that AEA injected intraglandu-
larly inhibited NE- and MC-induced salivary secretion in 
vivo and that AM251 and AM630 prevented this inhibi-
tion, suggesting that both CB1 and CB2 are implicated in 
the modulation of saliva secretion  [13] . CB2 mainly lo-
cated at the periphery of the acini could regulate the re-
lease of saliva from these cells to the salivary ducts. The 
function of CB1 in the SMG is more difficult to explain, 
since these receptors were not immunodetected in the 
vicinity of the acini. However, the immunodetection of 
CB1 in the ductal system suggests a paracrine effect from 
the duct cells to the acinar cells to reduce the volume of 
saliva. 
 Additionally, since CB1 and CB2 receptor antagonists 
increased the salivary secretion induced by lower doses 
of sialogogues, these findings indicate that there is an en-
dogenous endocannabinoid tone that could regulate sali-
vary secretion. 
 These evidences suggest that the endocannabinoid 
system involves similar mechanisms in the brain and in 
peripheral organs such as the SMG. The FRSK-induced 
AC activity is a useful experimental procedure to study 
CB receptor biologic activity in the brain as well as in the 
periphery. At least in our experimental paradigm, CB re-
ceptors activation seems to promote inhibitory actions at 
brain level, such as LHRH release diminution, and pe-
ripherally, such as decrease in salivary secretion. 
 Role of the Endocannabinoid System in the 
Blockade of the Reproductive Axis and the 
Inhibition of Salivary Secretion during Infection 
 Lipopolysaccharide (LPS), an integral part of the outer 
membrane of Gram-negative bacteria, is a major patho-
genic factor in septic shock. Macrophages are the prima-
ry targets of LPS, where the toxin interacts with the CD14 
protein/Toll-like receptor-4 complex to activate multiple 
signaling pathways. LPS induces the expression and re-
lease of cytokines such as TNF-  , interleukin (IL)-1, IL-6 
and IL-8, which have been implicated in the pathophysi-
ology of septic shock  [16] . Also, LPS induces the produc-
tion of different lipid mediators in macrophages, such as 
prostaglandins, leukotrienes and AEA  [17] . 
 Cannabinoid agonists are known to decrease neuro-
toxicity and AEA is able to promote anti-inflammatory 
responses in astrocytes via CB1 receptors  [18] . In addition 
to modulating cellular responsiveness to various cyto-
kines, AEA was also reported to alter its production un-
der different conditions. Studies in human peripheral 
blood mononuclear cells examining a wide variety of cy-
tokines demonstrated that AEA increased or decreased 
cytokine release depending upon drug concentration 
 [19] . Also, it was reported that both synthetic and endog-
enous cannabinoids inhibit the LPS-induced release of 
TNF-  from microglial cells  [20] and that LPS increased 
AEA levels in mouse peritoneal macrophages by induc-
ing AEA synthesis  [17] . 
 Regarding reproductive function, it is known that 
during endotoxemia induced by LPS, the hypothalamic-
gonadotropin axis is inhibited. Also, LPS seems to acti-
vate similar mechanisms in the inhibitory pathway of 
LHRH as those exerted by endocannabinoids, principal-
ly by increasing GABAergic activity  [21] . 
 It was reported that LPS leads to the suppression of 
LHRH pulse generator activity through a mechanism in-
volving TNF-  . This change was faithfully reflected in 
the luteinizing hormone secretory pattern  [22] . Further-
more, we demonstrated that AEA (50 ng/5   l) injected 
intracerebroventricularly reduced plasma luteinizing 
hormone levels in the rat  [23] , similarly to the reduction 
of gonadotropin levels observed in sheep during endotox-
emia induced by LPS  [24] .
 In this study, we demonstrated a connection between 
the neuroimmune and neuroendocannabinoid systems 
by showing the increase in AEA synthase activity in MBH 
removed from rats injected with LPS (5 mg/kg/3 h, intra-
peritoneally) compared to rats receiving vehicle. Addi-
tionally, we demonstrated that TNF-  (10 ng/5   l) in-
jected intracerebroventricularly increased the AEA syn-
thase activity measured ex vivo 3 h after the injections. 
Therefore, it is possible that LPS, through an increase in 
TNF-  production, enhances AEA synthase activity, 
thereby activating the endocannabinoid system to inhib-
it the release of LHRH. To confirm this hypothesis we 
measured the effect of TNF-  on LHRH release from 
MBH incubated in vitro. TNF-  significantly reduced 
FRSK-stimulated cAMP content and LHRH release and 
these effects were blocked by the CB1 antagonist AM251. 
These results suggest that the endocannabinoid system 
participates in neuroendocrine responses and immune 
responses mediated by TNF-  .
 On the other hand, it is well known that salivary secre-
tion is altered in different pathological states concomi-
tantly with other physiologic parameters. We previously 
demonstrated that LPS injected intraperitoneally inhibits 
salivary secretion by increasing prostaglandin production 
 [25] . Also, we recently demonstrated that LPS injected in-
traperitoneally increased AEA synthase activity in the 
SMG 3 h after the toxin injection. Therefore, we hypoth-
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esized that the inhibition of salivary secretion observed 
during inflammation could be mediated by the activa-
tion of the endocannabinoid system in the SMG. In fact, 
both AM251 and AM630 (6  !  10 –4  M ), CB1 and CB2 re-
ceptor antagonists, respectively, injected intraglandularly, 
blocked, at least partially, the inhibitory effect of LPS on 
MC-induced salivary secretion. The biological activity of 
CB1 and CB2 receptors in the SMG was confirmed by the 
experimental procedure of FRSK-induced AC activity, 
showing that AM251 was more efficient than AM630 in 
blocking the inhibitory effect of TNF-  on FRSK-stimu-
lated cAMP content in SMG incubated in vitro.
 In summary, these results demonstrate that during en-
dotoxemia induced by LPS the reproductive axis and sal-
ivary secretion are attenuated, at least in part, due to the 
activation of the endocannabinoid system that acts as an 
immunoprotector system.
 Role of the Endocannabinoid System in the
Ethanol-Induced Blockade of the Reproductive Axis 
and the Inhibition of Salivary Secretion 
 It is well known that ethanol (EtOH), similar to THC, 
can suppress reproductive function  [26] . Much evidence 
exists that EtOH exerts its pharmacological effects in the 
central nervous system by modulating the function of in-
tracellular signal transduction pathways by acting on 
several receptors. Since the actions of EtOH and THC on 
the hypothalamic-gonadotrophic axis are similar, we hy-
pothesized that the effects of EtOH might be mediated by 
the endocannabinoid system. 
 On the basis of in vitro experiments with MBH, we 
demonstrated that EtOH (100 m M ) inhibited the NMDA-
stimulated release of LHRH by increasing the release of 
GABA  [27] as well as AEA. Also, EtOH (100 m M ) inhib-
ited the FRSK-stimulated cAMP increase and LHRH re-
lease, inhibitory effects that were at least partially blocked 
by AM251, suggesting the involvement of CB1 receptors 
in the alcohol-induced blockade of reproductive function 
 [10] . The incomplete inhibition could be due to the pres-
ence of a second inhibitory pathway such as the opioid 
system, since it has been shown that EtOH increases the 
release of   -endorphin which also can inhibit LHRH re-
lease  [9] . 
 In these in vitro experiments, AEA synthase activity 
did not change after exposing MBH to EtOH (100 m M ) 
for 30 min. However, AEA synthase activity increased in 
MBH dissected 1 h after intragastric administration of 
EtOH (3 g/kg).
 On the other hand, it is known that alcohol consump-
tion decreases salivary secretion as does AEA. We hy-
pothesized that EtOH might act through the endocan-
nabinoid system to inhibit salivary secretion. Gastric
administration of EtOH (3 g/kg) in adult male rats inhib-
ited MC-stimulated saliva secretion, studied 1 h after in-
jection, which was partially restored by intraglandular 
injection of AM251 and AM630 (6  !  10 –4  M ). Moreover, 
AEA synthase activity was increased significantly in 
SMG removed 1 h after intragastric administration of 
EtOH (3 g/kg). Also, EtOH (100 m M ) significantly re-
duced the FRSK-increased cAMP content in SMG slices 
incubated in vitro for 30 min. This inhibitory effect was 
significantly blocked by the CB1 and CB2 receptor an-
tagonists. Therefore, the hyposalia observed after alcohol 
consumption could be due to CB receptor activation in 
the salivary glands.
 In summary, EtOH and the LPS-induced TNF-  re-
lease increase AEA synthesis in the MBH. This augmen-
tation of AEA production activates CB1 receptors that 
reduce cAMP, thereby activating GABAergic neurons 
that respond by increasing the release of GABA. Finally, 
GABA acts on GABA A receptors located on LHRH neu-
rons to inhibit LHRH release. Similarly, the inhibitory 
effect produced by alcohol and inflammation on salivary 
secretion is mediated, at least in part, by the endocan-
nabinoid system. In these cases, AEA synthase activity is 
increased and the endocannabinoid acts on both CB1 and 
CB2 receptors decreasing cAMP production, thereby 
conducing to the diminution of salivary secretion.
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